Malignant Bladder Neoplasm — Trials

Malignant Bladder Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 346
Recruiting: 177
Ph III recruiting: 23
Growth YoY: +17.9%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.3%
Trials / 1,000 deaths: 20 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (179)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06443944	An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG	available	—	—	CG Oncology, Inc.INDUSTRY	1	Sep 11, 2026	clinicaltrials
NCT04566393	Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies	available	—	—	xCuresINDUSTRY	1	Jun 4, 2026	clinicaltrials